One of our endearing traits as Americans is we want things big – supersized, if you will. 

That must be why questions such as “What is the starting dose of semaglutide?” and “What is the maximum dose of semaglutide I can take?” are common for first-time patients at Rivas Medical Weight Loss. As you will see below, the answers are not always “one-size-fits-all.”

What is the maximum dosage of semaglutide I can take?

• Maximum FDA-approved for weight loss (Wegovy): 2.4 mg weekly
• Maximum FDA-approved for diabetes (Ozempic): 2.0 mg weekly
• Investigational dose studied: 7.2 mg weekly (not FDA-approved)

In the U.S., the FDA guidelines currently cap the maximum suggested weekly dosage of semaglutide to 2.4 mg for injections. The new Wegovy pill, meanwhile, is approved for 25 mg daily. Learn more about the Wegovy injection-to-pills translation.

What About Higher Doses of Semaglutide?

Ironically, it’s the United Kingdom and not the USA that has led the way to approving higher dosage levels of semaglutide up to 7.2 mg per week. Here in the States, Wegovy manufacturer Novo Nordisk has filed for FDA approval of its injection to 7.2 mg. The request is expected to be approved at some point in 2026.

What results can we expect from a maximum weekly dosage of 7.2 mg?

The STEP UP trial, a Phase 3b study published in The Lancet Diabetes & Endocrinology in 2025, evaluated a 7.2 mg weekly injection dose in over 1,400 adults with obesity (BMI of 30 or higher) and without diabetes. The results were significant:

• Average weight loss of 20.7% of starting body weight over a span of 72 weeks among participants who stayed on treatment, compared to 17.5% with the standard 2.4 mg dose.
• More patients reached major milestones. More than 90% of participants on 7.2 mg lost at least 5% of their body weight, and about one in three lost 25% or more.
• Waist circumference improvements were also greater with the higher dose, with an average additional reduction of nearly 12 cm – or 4.72 inches – compared to placebo.

The safety profile at 7.2 mg was broadly consistent with what is already known about semaglutide. Gastrointestinal side effects (nausea, vomiting, diarrhea) were the most common, and most were mild to moderate. One new finding was a higher rate of dysaesthesia (tingling, burning, or unusual skin sensitivity) in the 7.2 mg group at about 23%, compared to 6% at 2.4 mg. Only 3.3% of patients on the higher dose stopped treatment because of GI-related side effects.

Weekly Dosing Chart

But not all patients will need to get to the max dosage or even that possible new 7.2 mg level very quickly – or at all. Semaglutide for weight loss follows a dosing schedule that gradually increases over a span of several months. This approach is designed to minimize gastrointestinal side effects and allow providers to assess how each patient responds before advancing to the next dose.

Below is a common dosing framework that many clinics follow for the different brands of weight loss drugs. Keep in mind that your own schedule may look a bit different based on how well you tolerate each increase, your medical history, other medications you’re taking, and what your doctor thinks is best for you.

*Investigational dose. The 7.2 mg injection dose has completed Phase 3b clinical trials (STEP UP) but is not yet FDA-approved. This dose is shown for educational context based on published clinical data. It is available only as a weekly injection; no oral or Ozempic equivalent exists at this strength. Your provider will inform you if and when this dose becomes available.

In most cases, patients notice a reduced appetite within the first week of semaglutide treatment. However, clinically meaningful weight loss usually occurs between 8 and 12 weeks of treatment.

Common side effects & management

Your doctor might hold off on raising the dose if any of the following occur:

• Lingering nausea, vomiting, or other ongoing side effects;
• Appetite suppression for most of the week, since this is a sign the medication is working at your current dose;
• Getting full faster than usual — this is the primary sign semaglutide is effective, even if you still feel some hunger;
• Still feeling hungry does not mean your dose needs to be raised — some hunger is normal and expected; the goal is not to eliminate hunger entirely.

Learn more about semaglutide side effects including common and serious symptoms

Clinical evidence shows that gradual titration improves treatment adherence. At Rivas Medical, for example, when we first started using semaglutide we found patients reported more side effects when they jumped from 0.5mg to 1.0mg per week. That led us to prescribe the 0.75mg dose.

Sometimes they never pass that dose of 0.75 mg. It can be a “sweet spot.”’ Or sometimes it’s  just used as a bridge to the 1.0mg dose. Either way, the 0.75 mg incremental dose is very well tolerated.

How Long Does it Take to Reach the Maintenance Dose?

For most patients, it takes 12-to-16 weeks to get to their full target dose of semaglutide, though it depends on how well they tolerate it and how their body responds. Some people move through the schedule a bit faster, while others need extra time at certain levels before progressing.

• Download printable Wegovy Weekly Injection Schedule pdf

Why the Same Dose Feels Stronger the Second Week?

If you look at the chart above, you will notice two lines — the weekly dose you receive, and the total amount building in your body over time. That gap between them reflects something clinically important.

Semaglutide has a half-life of approximately seven days, meaning roughly half of each week’s dose is still active in your system when you come in for your next injection. By Week 2 at the same dose, your body is not just experiencing that week’s injection — it is experiencing that dose on top of what is already there.

Here is a straightforward example: a patient starts at 1 mg. They come back the following week saying they do not feel much difference. In that moment, we have not failed the dose — the dose has not fully accumulated yet. We give them 1 mg again. But this week, they have approximately 1.5 mg of active medication in their body — as a simplified illustration, not a precise pharmacokinetic calculation. The week after that, closer to 1.75 mg. The medication is building toward a true steady state, which takes roughly four to five weeks at any given dose level.

This is one of the most common misunderstandings we see at Rivas. Patients interpret “same dose” as “no change.” But the pharmacology tells a different story. The dose is the same. The effect is increasing.

It is also why rushing to a higher dose in the first week or two — before steady state is reached — often leads to unnecessary side effects. The body needs time to calibrate.

 “Patients are sometimes surprised that we do not immediately increase their dose when they feel hungry early on. The medication is still ramping up. Patience at this stage almost always pays off.” — Dr. Paul Rivas

• Download printable Ozempic Weekly Injection pdf

Adjusting Dose & When to See Provider

Weight loss is rarely perfectly linear. Dose decisions should be based on patterns over multiple weeks, not a single weigh-in.

“We share the journey with the patient. We’re invested in their progress and adjust treatment based on how their body responds.” — Sophia Ro, PA-C

Plateaus Are Common (and Don’t Automatically Require a Higher Dose)

Many patients assume that if the scale pauses, the dose must be increased. In reality, a plateau can reflect hydration shifts, digestion changes, sleep quality, stress, strength training, or normal metabolic adaptation.

Providers typically evaluate the trend over multiple weeks before making any dosing changes. Increasing the dose during a short plateau can increase side effects without improving outcomes. Often, holding steady is the better clinical decision.

“Plateaus are a normal and expected part of the process.”
— Vincent Bottaro, PA-C

“Weight loss is not a linear journey. There may be weeks where the scale doesn’t move — that doesn’t mean the medication isn’t working.” — Mackenzie Murray, PA-C

Why Semaglutide Works Best as a High-Touch Medication

Some patients receive a prescription, follow the printed titration schedule, and reach their goal weight. Just as some people can walk into a gym, follow a general program, and get results.

But many people need structured progression, accountability, and expert adjustment to succeed.

Clinical trials use standardized escalation schedules designed for research consistency. Real patients vary in gastric sensitivity, appetite response, hydration patterns, and metabolic adaptation. A rigid timeline does not account for those differences.

Semaglutide works by slowing gastric emptying and altering central appetite signaling through GLP-1 receptor activation. Escalating too quickly increases nausea, reflux, and discontinuation risk. Staying too low may limit therapeutic benefit. The optimal dose sits at the intersection of tolerability and metabolic response — which is rarely identical between patients.

In our experience treating thousands of patients, small dose adjustments — including holding at a lower dose longer or modifying escalation timing — often determine whether someone tolerates therapy long enough to reach meaningful weight reduction.

“Almost every patient who reflects on their journey says the structure and support made the difference,” says Bottaro.

Frequently Asked Questions

Sources:

1. Mayo Clinic: Semaglutide (Subcutaneous Route)
2. Wegovy: Starting Wegovy Pill
3. Diabetes Care: Gradual Titration of Semaglutide Results in Better Tolerability
4. Ozempic: Dosing Information
5. Wharton S, Freitas P, Hjelmesaeth J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949-963. doi:10.1016/S2213-8587(25)00226-8. PubMed